

BOTOX[®] Cervical Dystonia Treatment Record

Patient name

Clinical rationale for BOTOX[®] injection: _____

Clinical rationale for EMG (if performed): _____

Comments: _____

Dilution Table

Diluent added (0.9% Sodium Chloride Injection)	Resulting Dose (Units/0.1 mL)
1.0mL	10.0 U
2.0 mL	5.0 U
4.0 mL	2.5 U
8.0 mL	1.25 U

Treatment date

Dilution (Units/mL)

Lot number(s)

Vial expiration date(s)

Note: These dilutions are calculated for an injection volume of 0.1 mL. A decrease or increase in the BOTOX[®] dose is also possible by administering a smaller or larger injection volume—from 0.05 mL (50% decrease in dose) to 0.15 mL (50% increase in dose).

BOTOX[®] (botulinum toxin type A) is indicated for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.

IMPORTANT SAFETY INFORMATION

Contraindications: BOTOX[®] treatment is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any ingredient in the formulation.

Warnings: Serious and/or immediate hypersensitivity reactions have been rarely reported. These reactions include anaphylaxis, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, further BOTOX[®] injection should be discontinued and appropriate medical therapy immediately instituted. Patients with peripheral motor neuropathic diseases (eg, amyotrophic lateral sclerosis or motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should only receive BOTOX[®] treatment with caution. Patients with neuromuscular disorders may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical BOTOX[®] doses.

Adverse events: There have been rare spontaneous reports of death, sometimes associated with dysphagia, pneumonia, and/or other significant debility or anaphylaxis, after treatment with botulinum toxin. There have been rare reports of adverse events involving the cardiovascular system. The most frequently reported adverse reactions in patients with cervical dystonia following BOTOX[®] injection are dysphagia (19%), upper respiratory infection (12%), neck pain (11%), and headache (11%).


Botulinum Toxin Type A
Focused On Innovation

P A T I E N T I N J E C T I O N R E C O R D

Semispinalis capitis *Typical BOTOX® Dosage: 50–150 U*
 Right: _____
 Left: _____

Sternocleidomastoid ^{1,2} *Typical BOTOX® Dosage: 15–75 U*
 Right: _____
 Left: _____

Trapezius *Typical BOTOX® Dosage: 50–100 U*
 Right: _____
 Left: _____

Splenius capitis ³
 Right: _____
 Left: _____

Longissimus
 Right: _____
 Left: _____

Splenius cervicis ³
 Right: _____
 Left: _____

Levator scapulae ⁴
 Right: _____
 Left: _____

F I L L I N N U M B E R O F U N I T S I N J E C T E D

Splenius capitis *Typical BOTOX® Dosage: 50–150 U*
 Right: _____
 Left: _____

Levator scapulae ⁴ *Typical BOTOX® Dosage: 25–100 U*
 Right: _____
 Left: _____

Trapezius *Typical BOTOX® Dosage: 50–100 U*
 Right: _____
 Left: _____

Sternocleidomastoid ^{1,2}
 Right: _____
 Left: _____

Scalene
 Right: _____
 Left: _____

Typical BOTOX® Dosage: 15–75 U
Typical BOTOX® Dosage: 15–50 U

1 Dosage reported in 25% to 75% of patients/total muscle groups (Units).
 2 Limiting the dose injected into the sternocleidomastoid muscle to ≤ 100 U may decrease the occurrence of dysphagia. If contributing, dose is always cut in half when injecting sternocleidomastoids for anterocollis. Patients with smaller neck muscle mass, or patients who require bilateral injections into the sternocleidomastoid muscle, have been reported to be at greater risk of dysphagia.
 3 When injecting in back of neck, it is critical that injections be symmetrical in order to avoid tilting of the head.
 4 Usually injected if shoulder is involved.

Some patients may require injections into additional muscles. Fill in additional locations/units injected below.

Sites Injected	No. Injections/Muscle	Units/Injection	Total Units/Muscle
Total Units Billed	<input style="width: 100px;" type="text"/>	Total Units Injected	<input style="width: 100px;" type="text"/>

Note to representative: Please provide full prescribing information when presenting this material.



©2006 Allergan, Inc., Irvine, CA 92612
 ®Marks owned by Allergan, Inc. www.botox.com 1-800-44BOTOX
 4960744

